YAP/TAZ at the Roots of Cancer

Cancer Cell

Volumn 29, Issue 6, 2016, Pages 783-803

  Zanconato, Francesca ^a   Cordenonsi, Michelangelo ^a   Piccolo, Stefano ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDES AND PROTEINS; TAZ PROTEIN; UNCLASSIFIED DRUG; YAP PROTEIN; HIPPO PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAZ PROTEIN, HUMAN; TRANSCRIPTION FACTOR; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; BREAST CANCER; CANCER CELL; CANCER STEM CELL; CELL CYCLE REGULATION; CELL PLASTICITY; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CONTACT INHIBITION; DRUG RESISTANCE; ENDOMETRIUM CARCINOMA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMANGIOENDOTHELIOMA; HUMAN; INFLAMMATION; KAPOSI SARCOMA; LIVER CANCER; LUNG CANCER; MALIGNANT MESOTHELIOMA; MECHANOTRANSDUCTION; MEDULLOBLASTOMA; MELANOMA; MENINGIOMA; METASTASIS; MULTIPLE MYELOMA; NEOPLASM; NEURILEMOMA; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHABDOMYOSARCOMA; SKIN CARCINOMA; STOMACH CANCER; TRANSITIONAL CELL CARCINOMA; UTERINE CERVIX CARCINOMA; ANIMAL; METABOLISM; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MECHANOTRANSDUCTION, CELLULAR; NEOPLASMS; NEOPLASTIC STEM CELLS; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR MICROENVIRONMENT;

EID: 84979544401     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.05.005     Document Type: Review

References (224)

1. Anakk, S., Bhosale, M., Schmidt, V.A., Johnson, R.L., Finegold, M.J., Moore, D.D., Bile acids activate YAP to promote liver carcinogenesis. Cell Rep. 5 (2013), 1060–1069.
2. Antonescu, C.R., Le Loarer, F., Mosquera, J.M., Sboner, A., Zhang, L., Chen, C.L., Chen, H.W., Pathan, N., Krausz, T., Dickson, B.C., et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 52 (2013), 775–784.
3. Aragona, M., Panciera, T., Manfrin, A., Giulitti, S., Michielin, F., Elvassore, N., Dupont, S., Piccolo, S., A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 154 (2013), 1047–1059.
4. Azzolin, L., Zanconato, F., Bresolin, S., Forcato, M., Basso, G., Bicciato, S., Cordenonsi, M., Piccolo, S., Role of TAZ as mediator of Wnt signaling. Cell 151 (2012), 1443–1456.
5. Azzolin, L., Panciera, T., Soligo, S., Enzo, E., Bicciato, S., Dupont, S., Bresolin, S., Frasson, C., Basso, G., Guzzardo, V., et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 158 (2014), 157–170.
6. Bai, H., Zhang, N., Xu, Y., Chen, Q., Khan, M., Potter, J.J., Nayar, S.K., Cornish, T., Alpini, G., Bronk, S., et al. Yes-associated protein regulates the hepatic response after bile duct ligation. Hepatology 56 (2012), 1097–1107.
7. Baia, G.S., Caballero, O.L., Orr, B.A., Lal, A., Ho, J.S., Cowdrey, C., Tihan, T., Mawrin, C., Riggins, G.J., Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Mol. Cancer Res. 10 (2012), 904–913.
8. Barry, E.R., Morikawa, T., Butler, B.L., Shrestha, K., de la Rosa, R., Yan, K.S., Fuchs, C.S., Magness, S.T., Smits, R., Ogino, S., et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 493 (2013), 106–110.
9. Bartucci, M., Dattilo, R., Moriconi, C., Pagliuca, A., Mottolese, M., Federici, G., Benedetto, A.D., Todaro, M., Stassi, G., Sperati, F., et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 34 (2015), 681–690.
10. Basu-Roy, U., Bayin, N.S., Rattanakorn, K., Han, E., Placantonakis, D.G., Mansukhani, A., Basilico, C., Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells. Nat. Commun., 6, 2015, 6411.
11. Benham-Pyle, B.W., Pruitt, B.L., Nelson, W.J., Cell adhesion. Mechanical strain induces E-cadherin-dependent Yap1 and beta-catenin activation to drive cell cycle entry. Science 348 (2015), 1024–1027.
12. Bhat, K.P., Salazar, K.L., Balasubramaniyan, V., Wani, K., Heathcock, L., Hollingsworth, F., James, J.D., Gumin, J., Diefes, K.L., Kim, S.H., et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 25 (2011), 2594–2609.
13. Bissell, M.J., Hines, W.C., Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 17 (2011), 320–329.
14. Blanpain, C., Fuchs, E., Stem cell plasticity. Plasticity of epithelial stem cells in tissue regeneration. Science, 344, 2014, 1242281.
15. Boin, A., Couvelard, A., Couderc, C., Brito, I., Filipescu, D., Kalamarides, M., Bedossa, P., De Koning, L., Danelsky, C., Dubois, T., et al. Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. Neuro Oncol. 16 (2014), 1196–1209.
16. Bueno, R., Stawiski, E.W., Goldstein, L.D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T.T., Jaiswal, B.S., Chirieac, L.R., et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48 (2016), 407–416.
17. Butcher, D.T., Alliston, T., Weaver, V.M., A tense situation: forcing tumour progression. Nat. Rev. Cancer 9 (2009), 108–122.
18. Byun, M.R., Hwang, J.H., Kim, A.R., Kim, K.M., Hwang, E.S., Yaffe, M.B., Hong, J.H., Canonical Wnt signalling activates TAZ through PP1A during osteogenic differentiation. Cell Death Differ. 21 (2014), 854–863.
19. Cai, J., Zhang, N., Zheng, Y., de Wilde, R.F., Maitra, A., Pan, D., The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 24 (2010), 2383–2388.
20. Cai, J., Maitra, A., Anders, R.A., Taketo, M.M., Pan, D., beta-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis. Genes Dev. 29 (2015), 1493–1506.
21. Calvo, F., Ege, N., Grande-Garcia, A., Hooper, S., Jenkins, R.P., Chaudhry, S.I., Harrington, K., Williamson, P., Moeendarbary, E., Charras, G., Sahai, E., Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat. Cell Biol. 15 (2013), 637–646.
22. Camargo, F.D., Gokhale, S., Johnnidis, J.B., Fu, D., Bell, G.W., Jaenisch, R., Brummelkamp, T.R., YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol. 17 (2007), 2054–2060.
23. Chan, S.W., Lim, C.J., Guo, K., Ng, C.P., Lee, I., Hunziker, W., Zeng, Q., Hong, W., A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 68 (2008), 2592–2598.
24. Chan, S.W., Lim, C.J., Loo, L.S., Chong, Y.F., Huang, C., Hong, W., TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J. Biol. Chem. 284 (2009), 14347–14358.
25. Chan, L.H., Wang, W., Yeung, W., Deng, Y., Yuan, P., Mak, K.K., Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. Oncogene 33 (2014), 4857–4866.
26. Chen, L., Chan, S.W., Zhang, X., Walsh, M., Lim, C.J., Hong, W., Song, H., Structural basis of YAP recognition by TEAD4 in the hippo pathway. Genes Dev. 24 (2010), 290–300.
27. Chen, D., Sun, Y., Wei, Y., Zhang, P., Rezaeian, A.H., Teruya-Feldstein, J., Gupta, S., Liang, H., Lin, H.K., Hung, M.C., Ma, L., LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat. Med. 18 (2012), 1511–1517.
28. Chen, Q., Zhang, N., Gray, R.S., Li, H., Ewald, A.J., Zahnow, C.A., Pan, D., A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev. 28 (2014), 432–437.
29. Chen, Q., Zhang, N., Xie, R., Wang, W., Cai, J., Choi, K.S., David, K.K., Huang, B., Yabuta, N., Nojima, H., et al. Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP. Genes Dev. 29 (2015), 1285–1297.
30. Cheng, H., Zhang, Z., Rodriguez-Barrueco, R., Borczuk, A., Liu, H., Yu, J., Silva, J.M., Cheng, S.K., Perez-Soler, R., Halmos, B., Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells. Oncotarget, 2015, 10.18632/oncotarget.6721.
31. Ciamporcero, E., Shen, H., Ramakrishnan, S., Yu Ku, S., Chintala, S., Shen, L., Adelaiye, R., Miles, K.M., Ullio, C., Pizzimenti, S., et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene 35 (2016), 1541–1553.
32. Clevers, H., Wnt/beta-catenin signaling in development and disease. Cell 127 (2006), 469–480.
33. Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., Inui, M., Montagner, M., Parenti, A.R., Poletti, A., et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147 (2011), 759–772.
34. Cottini, F., Hideshima, T., Xu, C., Sattler, M., Dori, M., Agnelli, L., ten Hacken, E., Bertilaccio, M.T., Antonini, E., Neri, A., et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat. Med. 20 (2014), 599–606.
35. Da, C.L., Xin, Y., Zhao, J., Luo, X.D., Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. World J. Gastroenterol. 15 (2009), 4055–4061.
36. Das, A., Fischer, R.S., Pan, D., Waterman, C.M., YAP nuclear localization in the absence of cell-cell contact is mediated by a filamentous actin-dependent, myosin II- and phospho-YAP independent pathway during ECM mechanosensing. J. Biol. Chem. 291 (2016), 6096–6110.
37. DeRan, M., Yang, J., Shen, C.H., Peters, E.C., Fitamant, J., Chan, P., Hsieh, M., Zhu, S., Asara, J.M., Zheng, B., et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Rep. 9 (2014), 495–503.
38. Di Agostino, S., Sorrentino, G., Ingallina, E., Valenti, F., Ferraiuolo, M., Bicciato, S., Piazza, S., Strano, S., Del Sal, G., Blandino, G., YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep. 17 (2015), 188–201.
39. Diaz-Martin, J., Lopez-Garcia, M.A., Romero-Perez, L., Atienza-Amores, M.R., Pecero, M.L., Castilla, M.A., Biscuola, M., Santon, A., Palacios, J., Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. Endocr. Relat. cancer 22 (2015), 443–454.
40. Diep, C.H., Zucker, K.M., Hostetter, G., Watanabe, A., Hu, C., Munoz, R.M., Von Hoff, D.D., Han, H., Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells. PLoS One, 7, 2012, e32783.
41. Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford, S.A., Gayyed, M.F., Anders, R.A., Maitra, A., Pan, D., Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130 (2007), 1120–1133.
42. Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. Role of YAP/TAZ in mechanotransduction. Nature 474 (2011), 179–183.
43. Eisinger-Mathason, T.S., Mucaj, V., Biju, K.M., Nakazawa, M.S., Gohil, M., Cash, T.P., Yoon, S.S., Skuli, N., Park, K.M., Gerecht, S., Simon, M.C., Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis. Proc. Natl. Acad. Sci. USA 112 (2015), E3402–E3411.
44. Ellison, D.W., Dalton, J., Kocak, M., Nicholson, S.L., Fraga, C., Neale, G., Kenney, A.M., Brat, D.J., Perry, A., Yong, W.H., et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 121 (2011), 381–396.
45. Enzo, E., Santinon, G., Pocaterra, A., Aragona, M., Bresolin, S., Forcato, M., Grifoni, D., Pession, A., Zanconato, F., Guzzo, G., et al. Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J. 34 (2015), 1349–1370.
46. Errani, C., Zhang, L., Sung, Y.S., Hajdu, M., Singer, S., Maki, R.G., Healey, J.H., Antonescu, C.R., A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 50 (2011), 644–653.
47. Feng, X., Degese, M.S., Iglesias-Bartolome, R., Vaque, J.P., Molinolo, A.A., Rodrigues, M., Zaidi, M.R., Ksander, B.R., Merlino, G., Sodhi, A., et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 25 (2014), 831–845.
48. Fernandez, L.A., Northcott, P.A., Dalton, J., Fraga, C., Ellison, D., Angers, S., Taylor, M.D., Kenney, A.M., YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev. 23 (2009), 2729–2741.
49. Fernandez, B.G., Gaspar, P., Bras-Pereira, C., Jezowska, B., Rebelo, S.R., Janody, F., Actin-Capping Protein and the Hippo pathway regulate F-actin and tissue growth in Drosophila. Development 138 (2011), 2337–2346.
50. Fernandez, L.A., Squatrito, M., Northcott, P., Awan, A., Holland, E.C., Taylor, M.D., Nahle, Z., Kenney, A.M., Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene 31 (2012), 1923–1937.
51. Fitamant, J., Kottakis, F., Benhamouche, S., Tian, H.S., Chuvin, N., Parachoniak, C.A., Nagle, J.M., Perera, R.M., Lapouge, M., Deshpande, V., et al. YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. Cell Rep., 2015, 10.1016/j.celrep.2015.02.027.
52. Fujii, M., Toyoda, T., Nakanishi, H., Yatabe, Y., Sato, A., Matsudaira, Y., Ito, H., Murakami, H., Kondo, Y., Kondo, E., et al. TGF-beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J. Exp. Med. 209 (2012), 479–494.
53. Gailite, I., Aerne, B.L., Tapon, N., Differential control of Yorkie activity by LKB1/AMPK and the Hippo/Warts cascade in the central nervous system. Proc. Natl. Acad. Sci. USA 112 (2015), E5169–E5178.
54. Galli, G.G., Carrara, M., Yuan, W.C., Valdes-Quezada, C., Gurung, B., Pepe-Mooney, B., Zhang, T., Geeven, G., Gray, N.S., de Laat, W., et al. YAP drives growth by controlling transcriptional pause release from dynamic enhancers. Mol. Cell 60 (2015), 328–337.
55. Garcia-Prat, L., Martinez-Vicente, M., Perdiguero, E., Ortet, L., Rodriguez-Ubreva, J., Rebollo, E., Ruiz-Bonilla, V., Gutarra, S., Ballestar, E., Serrano, A.L., et al. Autophagy maintains stemness by preventing senescence. Nature 529 (2016), 37–42.
56. Gaspar, P., Tapon, N., Sensing the local environment: actin architecture and Hippo signalling. Curr. Opin. Cell Biol. 31 (2014), 74–83.
57. George, N.M., Day, C.E., Boerner, B.P., Johnson, R.L., Sarvetnick, N.E., Hippo signaling regulates pancreas development through inactivation of Yap. Mol. Cell Biol. 32 (2012), 5116–5128.
58. Gregorieff, A., Liu, Y., Inanlou, M.R., Khomchuk, Y., Wrana, J.L., Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer. Nature 526 (2015), 715–718.
59. Guo, Y., Pan, Q., Zhang, J., Xu, X., Liu, X., Wang, Q., Yi, R., Xie, X., Yao, L., Liu, W., Shen, L., Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma. J. Cell. Biochem. 116 (2015), 2465–2475.
60. Halder, G., Dupont, S., Piccolo, S., Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat. Rev. Mol. Cell Biol. 13 (2012), 591–600.
61. Hall, C.A., Wang, R., Miao, J., Oliva, E., Shen, X., Wheeler, T., Hilsenbeck, S.G., Orsulic, S., Goode, S., Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 70 (2010), 8517–8525.
62. Han, S.X., Bai, E., Jin, G.H., He, C.C., Guo, X.J., Wang, L.J., Li, M., Ying, X., Zhu, Q., Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J. Immunol. Res., 2014, 2014, 261365.
63. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
64. Harvey, K.F., Pfleger, C.M., Hariharan, I.K., The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 114 (2003), 457–467.
65. Harvey, K.F., Zhang, X., Thomas, D.M., The Hippo pathway and human cancer. Nat. Rev. Cancer 13 (2013), 246–257.
66. Hayashi, H., Higashi, T., Yokoyama, N., Kaida, T., Sakamoto, K., Fukushima, Y., Ishimoto, T., Kuroki, H., Nitta, H., Hashimoto, D., et al. An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression. Cancer Res. 75 (2015), 4985–4997.
67. He, C., Mao, D., Hua, G., Lv, X., Chen, X., Angeletti, P.C., Dong, J., Remmenga, S.W., Rodabaugh, K.J., Zhou, J., et al. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Mol. Med. 7 (2015), 1426–1449.
68. Heallen, T., Zhang, M., Wang, J., Bonilla-Claudio, M., Klysik, E., Johnson, R.L., Martin, J.F., Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 332 (2011), 458–461.
69. Herr, K.J., Tsang, Y.H., Ong, J.W., Li, Q., Yap, L.L., Yu, W., Yin, H., Bogorad, R.L., Dahlman, J.E., Chan, Y.G., et al. Loss of alpha-catenin elicits a cholestatic response and impairs liver regeneration. Sci. Rep., 4, 2014, 6835.
70. Hiemer, S.E., Zhang, L., Kartha, V.K., Packer, T.S., Almershed, M., Noonan, V., Kukuruzinska, M., Bais, M.V., Monti, S., Varelas, X., A YAP/TAZ-regulated molecular signature is associated with oral squamous cell carcinoma. Mol. Cancer Res. 13 (2015), 957–968.
71. Hirata, E., Girotti, M.R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R., Sahai, E., Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer Cell 27 (2015), 574–588.
72. Hu, X., Xin, Y., Xiao, Y., Zhao, J., Overexpression of YAP1 is correlated with progression, metastasis and poor prognosis in patients with gastric carcinoma. Pathol. Oncol. Res. 20 (2014), 805–811.
73. Hua, G., Lv, X., He, C., Remmenga, S.W., Rodabough, K.J., Dong, J., Yang, L., Lele, S.M., Yang, P., Zhou, J., et al. YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. Oncogene 35 (2015), 2247–2265.
74. Huang, J., Wu, S., Barrera, J., Matthews, K., Pan, D., The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell 122 (2005), 421–434.
75. Imajo, M., Miyatake, K., Iimura, A., Miyamoto, A., Nishida, E., A molecular mechanism that links Hippo signalling to the inhibition of Wnt/beta-catenin signalling. EMBO J. 31 (2012), 1109–1122.
76. Jeong, W., Kim, S.B., Sohn, B.H., Park, Y.Y., Park, E.S., Kim, S.C., Kim, S.S., Johnson, R.L., Birrer, M., Bowtell, D.S., et al. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Res. 34 (2014), 811–817.
77. Jiao, S., Wang, H., Shi, Z., Dong, A., Zhang, W., Song, X., He, F., Wang, Y., Zhang, Z., Wang, W., et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 25 (2014), 166–180.
78. Justice, R.W., Zilian, O., Woods, D.F., Noll, M., Bryant, P.J., The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 9 (1995), 534–546.
79. Kanai, F., Marignani, P.A., Sarbassova, D., Yagi, R., Hall, R.A., Donowitz, M., Hisaminato, A., Fujiwara, T., Ito, Y., Cantley, L.C., Yaffe, M.B., TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 19 (2000), 6778–6791.
80. Kanellos, G., Zhou, J., Patel, H., Ridgway, R.A., Huels, D., Gurniak, C.B., Sandilands, E., Carragher, N.O., Sansom, O.J., Witke, W., et al. ADF and Cofilin1 control actin stress fibers, nuclear integrity, and cell survival. Cell Rep. 13 (2015), 1949–1964.
81. Kang, W., Tong, J.H., Chan, A.W., Lee, T.L., Lung, R.W., Leung, P.P., So, K.K., Wu, K., Fan, D., Yu, J., et al. Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin. Cancer Res. 17 (2011), 2130–2139.
82. Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.J., Sadanandam, A., Hu, B., et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158 (2014), 185–197.
83. Kim, J.H., Asthagiri, A.R., Matrix stiffening sensitizes epithelial cells to EGF and enables the loss of contact inhibition of proliferation. J. Cell Sci. 124 (2011), 1280–1287.
84. Kim, N.G., Koh, E., Chen, X., Gumbiner, B.M., E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc. Natl. Acad. Sci. USA 108 (2011), 11930–11935.
85. Kim, D.H., Kim, S.H., Lee, O.J., Huang, S.M., Kwon, J.L., Kim, J.M., Kim, J.Y., Seong, I.O., Song, K.S., Kim, K.H., Differential expression of Yes-associated protein and phosphorylated Yes-associated protein is correlated with expression of Ki-67 and phospho-ERK in colorectal adenocarcinoma. Histol. Histopathol. 28 (2013), 1483–1490.
86. Kim, G.J., Kim, H., Park, Y.N., Increased expression of Yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma. PLoS One, 8, 2013, e75449.
87. Kim, S.K., Jung, W.H., Koo, J.S., Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. Int. J. Clin. Exp. Pathol. 7 (2014), 3224–3234.
88. Kim, H.M., Jung, W.H., Koo, J.S., Expression of Yes-associated protein (YAP) in metastatic breast cancer. Int. J. Clin. Exp. Pathol. 8 (2015), 11248–11257.
89. Kim, T., Yang, S.J., Hwang, D., Song, J., Kim, M., Kyum Kim, S., Kang, K., Ahn, J., Lee, D., Kim, M.Y., et al. A basal-like breast cancer-specific role for SRF-IL6 in YAP-induced cancer stemness. Nat. Commun., 6, 2015, 10186.
90. Kim, M.H., Kim, J., Hong, H., Lee, S.H., Lee, J.K., Jung, E., Kim, J., Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. EMBO J. 35 (2016), 462–478.
91. Koontz, L.M., Liu-Chittenden, Y., Yin, F., Zheng, Y., Yu, J., Huang, B., Chen, Q., Wu, S., Pan, D., The Hippo effector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. Dev. Cell 25 (2013), 388–401.
92. Lallemand, D., Curto, M., Saotome, I., Giovannini, M., McClatchey, A.I., NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 17 (2003), 1090–1100.
93. Lamar, J.M., Stern, P., Liu, H., Schindler, J.W., Jiang, Z.G., Hynes, R.O., The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc. Natl. Acad. Sci. USA 109 (2012), E2441–E2450.
94. Lau, A.N., Curtis, S.J., Fillmore, C.M., Rowbotham, S.P., Mohseni, M., Wagner, D.E., Beede, A.M., Montoro, D.T., Sinkevicius, K.W., Walton, Z.E., et al. Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J. 33 (2014), 468–481.
95. Lavado, A., He, Y., Pare, J., Neale, G., Olson, E.N., Giovannini, M., Cao, X., Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators. Development 140 (2013), 3323–3334.
96. Lee, K.P., Lee, J.H., Kim, T.S., Kim, T.H., Park, H.D., Byun, J.S., Kim, M.C., Jeong, W.I., Calvisi, D.F., Kim, J.M., Lim, D.S., The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc. Natl. Acad. Sci. USA 107 (2010), 8248–8253.
97. Lee, M.J., Ran Byun, M., Furutani-Seiki, M., Hong, J.H., Jung, H.S., YAP and TAZ regulate skin wound healing. J. Invest. Dermatol. 134 (2014), 518–525.
98. Lee, K.W., Lee, S.S., Kim, S.B., Sohn, B.H., Lee, H.S., Jang, H.J., Park, Y.Y., Kopetz, S., Kim, S.S., Oh, S.C., Lee, J.S., Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. Clin. Cancer Res. 21 (2015), 357–364.
99. Li, H., Wolfe, A., Septer, S., Edwards, G., Zhong, X., Abdulkarim, A.B., Ranganathan, S., Apte, U., Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int. 32 (2012), 38–47.
100. Li, Q., Li, S., Mana-Capelli, S., Roth Flach, R.J., Danai, L.V., Amcheslavsky, A., Nie, Y., Kaneko, S., Yao, X., Chen, X., et al. The conserved misshapen-warts-Yorkie pathway acts in enteroblasts to regulate intestinal stem cells in Drosophila. Dev. Cell 31 (2014), 291–304.
101. Li, J., Gao, E., Vite, A., Yi, R., Gomez, L., Goossens, S., van Roy, F., Radice, G.L., Alpha-catenins control cardiomyocyte proliferation by regulating Yap activity. Circ. Res. 116 (2015), 70–79.
102. Li, S., Yu, Z., Chen, S.S., Li, F., Lei, C.Y., Chen, X.X., Bao, J.M., Luo, Y., Lin, G.Z., Pang, S.Y., Tan, W.L., The YAP1 oncogene contributes to bladder cancer cell proliferation and migration by regulating the H19 long noncoding RNA. Urol. Oncol. 33 (2015), 427.e1–427.e10.
103. Li, Y.W., Shen, H., Frangou, C., Yang, N., Guo, J., Xu, B., Bshara, W., Shepherd, L., Zhu, Q., Wang, J., et al. Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis. Cell Cycle 14 (2015), 146–156.
104. Li, Z., Wang, Y., Zhu, Y., Yuan, C., Wang, D., Zhang, W., Qi, B., Qiu, J., Song, X., Ye, J., et al. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. Mol. Oncol. 9 (2015), 1091–1105.
105. Li, P., Silvis, M.R., Honaker, Y., Lien, W.H., Arron, S.T., Vasioukhin, V., AlphaE-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway. Genes Dev. 30 (2016), 798–811.
106. Liang, N., Zhang, C., Dill, P., Panasyuk, G., Pion, D., Koka, V., Gallazzini, M., Olson, E.N., Lam, H., Henske, E.P., et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J. Exp. Med. 211 (2014), 2249–2263.
107. Lin, C., Yao, E., Chuang, P.T., A conserved MST1/2-YAP axis mediates Hippo signaling during lung growth. Dev. Biol. 403 (2015), 101–113.
108. Lin, C.H., Pelissier, F.A., Zhang, H., Lakins, J., Weaver, V.M., Park, C., LaBarge, M.A., Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors. Mol. Biol. Cell 26 (2015), 3946–3953.
109. Lin, L., Sabnis, A.J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J.J., Lu, X., et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet. 47 (2015), 250–256.
110. Liu, J.Y., Li, Y.H., Lin, H.X., Liao, Y.J., Mai, S.J., Liu, Z.W., Zhang, Z.L., Jiang, L.J., Zhang, J.X., Kung, H.F., et al. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer, 13, 2013, 349.
111. Liu, T., Liu, Y., Gao, H., Meng, F., Yang, S., Lou, G., Clinical significance of yes-associated protein overexpression in cervical carcinoma: the differential effects based on histotypes. Int. J. Gynecol. Cancer 23 (2013), 735–742.
112. Liu, G., Yu, F.X., Kim, Y.C., Meng, Z., Naipauer, J., Looney, D.J., Liu, X., Gutkind, J.S., Mesri, E.A., Guan, K.L., Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway. Oncogene 34 (2015), 3536–3546.
113. Liu, X., Li, H., Rajurkar, M., Li, Q., Cotton, J.L., Ou, J., Zhu, L.J., Goel, H.L., Mercurio, A.M., Park, J.S., et al. Tead and AP1 coordinate transcription and motility. Cell Rep. 14 (2016), 1169–1180.
114. Liu-Chittenden, Y., Huang, B., Shim, J.S., Chen, Q., Lee, S.J., Anders, R.A., Liu, J.O., Pan, D., Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26 (2012), 1300–1305.
115. Low, B.C., Pan, C.Q., Shivashankar, G.V., Bershadsky, A., Sudol, M., Sheetz, M., YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. FEBS Lett. 588 (2014), 2663–2670.
116. Lu, L., Li, Y., Kim, S.M., Bossuyt, W., Liu, P., Qiu, Q., Wang, Y., Halder, G., Finegold, M.J., Lee, J.S., Johnson, R.L., Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc. Natl. Acad. Sci. USA 107 (2010), 1437–1442.
117. Lucas, E.P., Khanal, I., Gaspar, P., Fletcher, G.C., Polesello, C., Tapon, N., Thompson, B.J., The Hippo pathway polarizes the actin cytoskeleton during collective migration of Drosophila border cells. J. Cell Biol. 201 (2013), 875–885.
118. Mana-Capelli, S., Paramasivam, M., Dutta, S., McCollum, D., Angiomotins link F-actin architecture to Hippo pathway signaling. Mol. Biol. Cell 25 (2014), 1676–1685.
119. Mao, B., Hu, F., Cheng, J., Wang, P., Xu, M., Yuan, F., Meng, S., Wang, Y., Yuan, Z., Bi, W., SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene 33 (2014), 1468–1474.
120. Martin-Belmonte, F., Perez-Moreno, M., Epithelial cell polarity, stem cells and cancer. Nat. Rev. Cancer 12 (2011), 23–38.
121. Meng, Z., Moroishi, T., Mottier-Pavie, V., Plouffe, S.W., Hansen, C.G., Hong, A.W., Park, H.W., Mo, J.S., Lu, W., Lu, S., et al. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat. Commun., 6, 2015, 8357.
122. Meng, Z., Moroishi, T., Guan, K.L., Mechanisms of Hippo pathway regulation. Genes Dev. 30 (2016), 1–17.
123. Menzel, M., Meckbach, D., Weide, B., Toussaint, N.C., Schilbach, K., Noor, S., Eigentler, T., Ikenberg, K., Busch, C., Quintanilla-Martinez, L., et al. In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival. Pigment Cell Melanoma Res. 27 (2014), 671–673.
124. Mo, J.S., Meng, Z., Kim, Y.C., Park, H.W., Hansen, C.G., Kim, S., Lim, D.S., Guan, K.L., Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat. Cell Biol. 17 (2015), 500–510.
125. Mohseni, M., Sun, J., Lau, A., Curtis, S., Goldsmith, J., Fox, V.L., Wei, C., Frazier, M., Samson, O., Wong, K.K., et al. A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat. Cell Biol. 16 (2014), 108–117.
126. Morvaridi, S., Dhall, D., Greene, M.I., Pandol, S.J., Wang, Q., Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis. Sci. Rep., 5, 2015, 16759.
127. Murakami, H., Mizuno, T., Taniguchi, T., Fujii, M., Ishiguro, F., Fukui, T., Akatsuka, S., Horio, Y., Hida, T., Kondo, Y., et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 71 (2011), 873–883.
128. Muramatsu, T., Imoto, I., Matsui, T., Kozaki, K., Haruki, S., Sudol, M., Shimada, Y., Tsuda, H., Kawano, T., Inazawa, J., YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis 32 (2011), 389–398.
129. Nallet-Staub, F., Marsaud, V., Li, L., Gilbert, C., Dodier, S., Bataille, V., Sudol, M., Herlyn, M., Mauviel, A., Pro-invasive activity of the hippo pathway effectors YAP and TAZ in cutaneous melanoma. J. Invest. Dermatol. 134 (2014), 123–132.
130. Nguyen, L.T., Tretiakova, M.S., Silvis, M.R., Lucas, J., Klezovitch, O., Coleman, I., Bolouri, H., Kutyavin, V.I., Morrissey, C., True, L.D., et al. ERG activates the YAP1 transcriptional program and induces the development of age-related prostate tumors. Cancer Cell 27 (2015), 797–808.
131. Noguchi, S., Saito, A., Horie, M., Mikami, Y., Suzuki, H.I., Morishita, Y., Ohshima, M., Abiko, Y., Mattsson, J.S., Konig, H., et al. An integrative analysis of the tumorigenic role of TAZ in human non-small cell lung cancer. Clin. Cancer Res. 20 (2014), 4660–4672.
132. Nowell, C.S., Odermatt, P.D., Azzolin, L., Hohnel, S., Wagner, E.F., Fantner, G.E., Lutolf, M.P., Barrandon, Y., Piccolo, S., Radtke, F., Chronic inflammation imposes aberrant cell fate in regenerating epithelia through mechanotransduction. Nat. Cell Biol. 18 (2015), 168–180.
133. O'Hayre, M., Vazquez-Prado, J., Kufareva, I., Stawiski, E.W., Handel, T.M., Seshagiri, S., Gutkind, J.S., The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat. Rev. Cancer 13 (2013), 412–424.
134. Oh, J.E., Ohta, T., Satomi, K., Foll, M., Durand, G., McKay, J., Le Calvez-Kelm, F., Mittelbronn, M., Brokinkel, B., Paulus, W., Ohgaki, H., Alterations in the NF2/LATS1/LATS2/YAP pathway in schwannomas. J. Neuropathol. Exp. Neurol. 74 (2015), 952–959.
135. Orr, B.A., Bai, H., Odia, Y., Jain, D., Anders, R.A., Eberhart, C.G., Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J. Neuropathol. Exp. Neurol. 70 (2011), 568–577.
136. Pan, D., The hippo signaling pathway in development and cancer. Dev. Cell 19 (2010), 491–505.
137. Pan, J., Li, S., Chi, P., Xu, Z., Lu, X., Huang, Y., Lentivirus-mediated RNA interference targeting WWTR1 in human colorectal cancer cells inhibits cell proliferation in vitro and tumor growth in vivo. Oncol. Rep. 28 (2012), 179–185.
138. Park, H.W., Kim, Y.C., Yu, B., Moroishi, T., Mo, J.S., Plouffe, S.W., Meng, Z., Lin, K.C., Yu, F.X., Alexander, C.M., et al. Alternative Wnt signaling activates YAP/TAZ. Cell 162 (2015), 780–794.
139. Pearson, H.B., Perez-Mancera, P.A., Dow, L.E., Ryan, A., Tennstedt, P., Bogani, D., Elsum, I., Greenfield, A., Tuveson, D.A., Simon, R., Humbert, P.O., SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J. Clin. Invest. 121 (2011), 4257–4267.
140. Perra, A., Kowalik, M.A., Ghiso, E., Ledda-Columbano, G.M., Di Tommaso, L., Angioni, M.M., Raschioni, C., Testore, E., Roncalli, M., Giordano, S., Columbano, A., YAP activation is an early event and a potential therapeutic target in liver cancer development. J. Hepatol. 61 (2014), 1088–1096.
141. Piccolo, S., Dupont, S., Cordenonsi, M., The biology of YAP/TAZ: hippo signaling and beyond. Physiol. Rev. 94 (2014), 1287–1312.
142. Pobbati, A.V., Han, X., Hung, A.W., Weiguang, S., Huda, N., Chen, G.Y., Kang, C., Chia, C.S., Luo, X., Hong, W., Poulsen, A., Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy. Structure 23 (2015), 2076–2086.
143. Rashidian, J., Le Scolan, E., Ji, X., Zhu, Q., Mulvihill, M.M., Nomura, D., Luo, K., Ski regulates Hippo and TAZ signaling to suppress breast cancer progression. Sci. Signal., 8, 2015, ra14.
144. Reginensi, A., Scott, R.P., Gregorieff, A., Bagherie-Lachidan, M., Chung, C., Lim, D.S., Pawson, T., Wrana, J., McNeill, H., Yap- and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development. PLoS Genet., 9, 2013, e1003380.
145. Ren, F., Zhang, L., Jiang, J., Hippo signaling regulates Yorkie nuclear localization and activity through 14-3-3 dependent and independent mechanisms. Dev. Biol. 337 (2010), 303–312.
146. Romero-Perez, L., Garcia-Sanz, P., Mota, A., Leskela, S., Hergueta-Redondo, M., Diaz-Martin, J., Lopez-Garcia, M.A., Castilla, M.A., Martinez-Ramirez, A., Soslow, R.A., et al. A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer. Mod. Pathol. 28 (2015), 1492–1503.
147. Rosenbluh, J., Nijhawan, D., Cox, A.G., Li, X., Neal, J.T., Schafer, E.J., Zack, T.I., Wang, X., Tsherniak, A., Schinzel, A.C., et al. Beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151 (2012), 1457–1473.
148. Sansores-Garcia, L., Bossuyt, W., Wada, K., Yonemura, S., Tao, C., Sasaki, H., Halder, G., Modulating F-actin organization induces organ growth by affecting the Hippo pathway. EMBO J. 30 (2011), 2325–2335.
149. Schlegelmilch, K., Mohseni, M., Kirak, O., Pruszak, J., Rodriguez, J.R., Zhou, D., Kreger, B.T., Vasioukhin, V., Avruch, J., Brummelkamp, T.R., Camargo, F.D., Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 144 (2011), 782–795.
150. Serrano, I., McDonald, P.C., Lock, F., Muller, W.J., Dedhar, S., Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat. Commun., 4, 2013, 2976.
151. Shao, D.D., Xue, W., Krall, E.B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A.C., Sood, S., Rosenbluh, J., Kim, J.W., et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158 (2014), 171–184.
152. Sheen-Chen, S.M., Huang, C.Y., Tsai, C.H., Liu, Y.W., Wu, S.C., Huang, C.C., Eng, H.L., Chan, Y.C., Ko, S.F., Tang, R.P., Yes-associated protein is not an independent prognostic marker in breast cancer. Anticancer Res. 32 (2012), 3321–3325.
153. Shen, S., Guo, X., Yan, H., Lu, Y., Ji, X., Li, L., Liang, T., Zhou, D., Feng, X.H., Zhao, J.C., et al. A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. Cell Res. 25 (2015), 997–1012.
154. Sheng, X., Li, W.B., Wang, D.L., Chen, K.H., Cao, J.J., Luo, Z., He, J., Li, M.C., Liu, W.J., Yu, C., YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells. Mol. Med. Rep. 12 (2015), 4867–4876.
155. Silvis, M.R., Kreger, B.T., Lien, W.H., Klezovitch, O., Rudakova, G.M., Camargo, F.D., Lantz, D.M., Seykora, J.T., Vasioukhin, V., Alpha-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1. Sci. Signal., 4, 2011, ra33.
156. Skibinski, A., Breindel, J.L., Prat, A., Galvan, P., Smith, E., Rolfs, A., Gupta, P.B., Labaer, J., Kuperwasser, C., The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep. 6 (2014), 1059–1072.
157. Song, H., Mak, K.K., Topol, L., Yun, K., Hu, J., Garrett, L., Chen, Y., Park, O., Chang, J., Simpson, R.M., et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc. Natl. Acad. Sci. USA 107 (2010), 1431–1436.
158. Song, M., Cheong, J.H., Kim, H., Noh, S.H., Kim, H., Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. Anticancer Res. 32 (2012), 3827–3834.
159. Song, S., Ajani, J.A., Honjo, S., Maru, D.M., Chen, Q., Scott, A.W., Heallen, T.R., Xiao, L., Hofstetter, W.L., Weston, B., et al. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res. 74 (2014), 4170–4182.
160. Song, Q., Mao, B., Cheng, J., Gao, Y., Jiang, K., Chen, J., Yuan, Z., Meng, S., YAP enhances autophagic flux to promote breast cancer cell survival in response to nutrient deprivation. PLoS One, 10, 2015, e0120790.
161. Song, S., Honjo, S., Jin, J., Chang, S.S., Scott, A.W., Chen, Q., Kalhor, N., Correa, A.M., Hofstetter, W.L., Albarracin, C.T., et al. The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clin. Cancer Res. 21 (2015), 2580–2590.
162. Sorrentino, G., Ruggeri, N., Specchia, V., Cordenonsi, M., Mano, M., Dupont, S., Manfrin, A., Ingallina, E., Sommaggio, R., Piazza, S., et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol. 16 (2014), 357–366.
163. Stein, C., Bardet, A.F., Roma, G., Bergling, S., Clay, I., Ruchti, A., Agarinis, C., Schmelzle, T., Bouwmeester, T., Schubeler, D., Bauer, A., YAP1 exerts its transcriptional control via TEAD-mediated activation of enhancers. PLoS Genet., 11, 2015, e1005465.
164. Striedinger, K., VandenBerg, S.R., Baia, G.S., McDermott, M.W., Gutmann, D.H., Lal, A., The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia 10 (2008), 1204–1212.
165. Su, L.L., Ma, W.X., Yuan, J.F., Shao, Y., Xiao, W., Jiang, S.J., Expression of Yes-associated protein in non-small cell lung cancer and its relationship with clinical pathological factors. Chin Med. J. (Engl.) 125 (2012), 4003–4008.
166. Su, T., Bondar, T., Zhou, X., Zhang, C., He, H., Medzhitov, R., Two-signal requirement for growth-promoting function of Yap in hepatocytes. Elife, 4, 2015, 10.7554/eLife.02948.
167. Sudol, M., Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 9 (1994), 2145–2152.
168. Tanahashi, K., Natsume, A., Ohka, F., Motomura, K., Alim, A., Tanaka, I., Senga, T., Harada, I., Fukuyama, R., Sumiyoshi, N., et al. Activation of yes-associated protein in low-grade meningiomas is regulated by merlin, cell density, and extracellular matrix stiffness. J. Neuropathol. Exp. Neurol. 74 (2015), 704–709.
169. Tanas, M.R., Ma, S., Jadaan, F.O., Ng, C.K., Weigelt, B., Reis-Filho, J.S., Rubin, B.P., Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein. Oncogene 35 (2015), 929–938.
170. Taniguchi, K., Wu, L.W., Grivennikov, S.I., de Jong, P.R., Lian, I., Yu, F.X., Wang, K., Ho, S.B., Boland, B.S., Chang, J.T., et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 519 (2015), 57–62.
171. Tao, J., Calvisi, D.F., Ranganathan, S., Cigliano, A., Zhou, L., Singh, S., Jiang, L., Fan, B., Terracciano, L., Armeanu-Ebinger, S., et al. Activation of beta-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology 147 (2014), 690–701.
172. Tapon, N., Harvey, K.F., Bell, D.W., Wahrer, D.C., Schiripo, T.A., Haber, D., Hariharan, I.K., Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 110 (2002), 467–478.
173. Tian, W., Yu, J., Tomchick, D.R., Pan, D., Luo, X., Structural and functional analysis of the YAP-binding domain of human TEAD2. Proc. Natl. Acad. Sci. USA 107 (2010), 7293–7298.
174. Tian, T., Li, A., Lu, H., Luo, R., Zhang, M., Li, Z., TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells. Biochem. Biophys. Res. Commun. 463 (2015), 638–643.
175. Tremblay, A.M., Missiaglia, E., Galli, G.G., Hettmer, S., Urcia, R., Carrara, M., Judson, R.N., Thway, K., Nadal, G., Selfe, J.L., et al. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Cancer Cell 26 (2014), 273–287.
176. Tsujiura, M., Mazack, V., Sudol, M., Kaspar, H.G., Nash, J., Carey, D.J., Gogoi, R., Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer. PLoS One, 9, 2014, e100974.
177. Van Keymeulen, A., Lee, M.Y., Ousset, M., Brohee, S., Rorive, S., Giraddi, R.R., Wuidart, A., Bouvencourt, G., Dubois, C., Salmon, I., et al. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature 525 (2015), 119–123.
178. Verfaillie, A., Imrichova, H., Atak, Z.K., Dewaele, M., Rambow, F., Hulselmans, G., Christiaens, V., Svetlichnyy, D., Luciani, F., Van den Mooter, L., et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat. Commun., 6, 2015, 6683.
179. Vici, P., Mottolese, M., Pizzuti, L., Barba, M., Sperati, F., Terrenato, I., Di Benedetto, A., Natoli, C., Gamucci, T., Angelucci, D., et al. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Oncotarget 5 (2014), 9619–9625.
180. Virchow, R., Die cellularpathologie in ihrer begründung auf physiologische und pathologische gewebelehre. 1858, A. Hirschwald, Berlin.
181. Wada, K., Itoga, K., Okano, T., Yonemura, S., Sasaki, H., Hippo pathway regulation by cell morphology and stress fibers. Development 138 (2011), 3907–3914.
182. Wang, Y., Dong, Q., Zhang, Q., Li, Z., Wang, E., Qiu, X., Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci. 101 (2010), 1279–1285.
183. Wang, X., Su, L., Ou, Q., Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur. J. Cancer 48 (2012), 1227–1234.
184. Wang, L., Shi, S., Guo, Z., Zhang, X., Han, S., Yang, A., Wen, W., Zhu, Q., Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One, 8, 2013, e65539.
185. Wang, Y., Xie, C., Li, Q., Xu, K., Wang, E., Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour Biol. 34 (2013), 2169–2174.
186. Wang, Z., Wu, Y., Wang, H., Zhang, Y., Mei, L., Fang, X., Zhang, X., Zhang, F., Chen, H., Liu, Y., et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc. Natl. Acad. Sci. USA 111 (2014), E89–E98.
187. Wang, Q., Xu, Z., An, Q., Jiang, D., Wang, L., Liang, B., Li, Z., TAZ promotes epithelial to mesenchymal transition via the upregulation of connective tissue growth factor expression in neuroblastoma cells. Mol. Med. Rep. 11 (2015), 982–988.
188. Wang, W., Xiao, Z.D., Li, X., Aziz, K.E., Gan, B., Johnson, R.L., Chen, J., AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat. Cell Biol. 17 (2015), 490–499.
189. Wang, G., Lu, X., Dey, P., Deng, P., Wu, C.C., Jiang, S., Fang, Z., Zhao, K., Konaparthi, R., Hua, S., et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. 6 (2016), 80–95.
190. Wu, S., Huang, J., Dong, J., Pan, D., hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 114 (2003), 445–456.
191. Xia, Y., Chang, T., Wang, Y., Liu, Y., Li, W., Li, M., Fan, H.Y., YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS One, 9, 2014, e91770.
192. Xiao, W., Wang, J., Ou, C., Zhang, Y., Ma, L., Weng, W., Pan, Q., Sun, F., Mutual interaction between YAP and c-Myc is critical for carcinogenesis in liver cancer. Biochem. Biophys. Res. Commun. 439 (2013), 167–172.
193. Xiao, H., Wu, L., Zheng, H., Li, N., Wan, H., Liang, G., Zhao, Y., Liang, J., Expression of Yes-associated protein in cervical squamous epithelium lesions. Int. J. Gynecol. Cancer 24 (2014), 1575–1582.
194. Xiao, H., Jiang, N., Zhou, B., Liu, Q., Du, C., TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma. Cancer Sci. 106 (2015), 151–159.
195. Xie, M., Zhang, L., He, C.S., Hou, J.H., Lin, S.X., Hu, Z.H., Xu, F., Zhao, H.Y., Prognostic significance of TAZ expression in resected non-small cell lung cancer. J. Thorac. Oncol. 7 (2012), 799–807.
196. Xu, T., Wang, W., Zhang, S., Stewart, R.A., Yu, W., Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development 121 (1995), 1053–1063.
197. Xu, M.Z., Yao, T.J., Lee, N.P., Ng, I.O., Chan, Y.T., Zender, L., Lowe, S.W., Poon, R.T., Luk, J.M., Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115 (2009), 4576–4585.
198. Xu, M.Z., Chan, S.W., Liu, A.M., Wong, K.F., Fan, S.T., Chen, J., Poon, R.T., Zender, L., Lowe, S.W., Hong, W., Luk, J.M., AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 30 (2011), 1229–1240.
199. Yang, S., Zhang, L., Purohit, V., Shukla, S.K., Chen, X., Yu, F., Fu, K., Chen, Y., Solheim, J., Singh, P.K., et al. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget 6 (2015), 36019–36031.
200. Yeo, M.K., Kim, S.H., Kim, J.M., Huang, S.M., Kim, M.R., Song, K.S., Kim, K.H., Correlation of expression of phosphorylated and non-phosphorylated Yes-associated protein with clinicopathological parameters in esophageal squamous cell carcinoma in a Korean population. Anticancer Res. 32 (2012), 3835–3840.
201. Yimlamai, D., Christodoulou, C., Galli, G.G., Yanger, K., Pepe-Mooney, B., Gurung, B., Shrestha, K., Cahan, P., Stanger, B.Z., Camargo, F.D., Hippo pathway activity influences liver cell fate. Cell 157 (2014), 1324–1338.
202. Yin, F., Yu, J., Zheng, Y., Chen, Q., Zhang, N., Pan, D., Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 154 (2013), 1342–1355.
203. Yu, F.X., Zhao, B., Panupinthu, N., Jewell, J.L., Lian, I., Wang, L.H., Zhao, J., Yuan, H., Tumaneng, K., Li, H., et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150 (2012), 780–791.
204. Yu, F.X., Luo, J., Mo, J.S., Liu, G., Kim, Y.C., Meng, Z., Zhao, L., Peyman, G., Ouyang, H., Jiang, W., et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 25 (2014), 822–830.
205. Yuan, M., Tomlinson, V., Lara, R., Holliday, D., Chelala, C., Harada, T., Gangeswaran, R., Manson-Bishop, C., Smith, P., Danovi, S.A., et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ. 15 (2008), 1752–1759.
206. Yue, G., Sun, X., Gimenez-Capitan, A., Shen, J., Yu, L., Teixido, C., Guan, W., Rosell, R., Liu, B., Wei, J., TAZ is highly expressed in gastric signet ring cell carcinoma. Biomed. Res. Int., 2014, 2014, 393064.
207. Yuen, H.F., McCrudden, C.M., Huang, Y.H., Tham, J.M., Zhang, X., Zeng, Q., Zhang, S.D., Hong, W., TAZ expression as a prognostic indicator in colorectal cancer. PLoS One, 8, 2013, e54211.
208. Zanconato, F., Piccolo, S., Eradicating tumor drug resistance at its YAP-biomechanical roots. EMBO J. 35 (2015), 459–461.
209. Zanconato, F., Forcato, M., Battilana, G., Azzolin, L., Quaranta, E., Bodega, B., Rosato, A., Bicciato, S., Cordenonsi, M., Piccolo, S., Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat. Cell Biol. 17 (2015), 1218–1227.
210. Zender, L., Spector, M.S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J., Fan, S.T., Luk, J.M., Wigler, M., Hannon, G.J., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125 (2006), 1253–1267.
211. Zhan, L., Rosenberg, A., Bergami, K.C., Yu, M., Xuan, Z., Jaffe, A.B., Allred, C., Muthuswamy, S.K., Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell 135 (2008), 865–878.
212. Zhang, N., Bai, H., David, K.K., Dong, J., Zheng, Y., Cai, J., Giovannini, M., Liu, P., Anders, R.A., Pan, D., The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 19 (2010), 27–38.
213. Zhang, X., George, J., Deb, S., Degoutin, J.L., Takano, E.A., Fox, S.B., AOCS Study Group, Bowtell, D.D., Harvey, K.F., The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 30 (2011), 2810–2822.
214. Zhang, Y.H., Li, B., Shen, L., Shen, Y., Chen, X.D., The role and clinical significance of YES-associated protein 1 in human osteosarcoma. Int. J. Immunopathol. Pharmacol. 26 (2013), 157–167.
215. Zhang, W., Gao, Y., Li, P., Shi, Z., Guo, T., Li, F., Han, X., Feng, Y., Zheng, C., Wang, Z., et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 24 (2014), 331–343.
216. Zhang, W., Nandakumar, N., Shi, Y., Manzano, M., Smith, A., Graham, G., Gupta, S., Vietsch, E.E., Laughlin, S.Z., Wadhwa, M., et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci. Signal., 7, 2014, ra42.
217. Zhang, L., Yang, S., Chen, X., Stauffer, S., Yu, F., Lele, S.M., Fu, K., Datta, K., Palermo, N., Chen, Y., Dong, J., The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol. Cell Biol. 35 (2015), 1350–1362.
218. Zhang, W., Gao, Y., Li, F., Tong, X., Ren, Y., Han, X., Yao, S., Long, F., Yang, Z., Fan, H., et al. YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin. Cancer Res. 75 (2015), 4450–4457.
219. Zhao, B., Wei, X., Li, W., Udan, R.S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21 (2007), 2747–2761.
220. Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J.D., Wang, C.Y., Chinnaiyan, A.M., et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22 (2008), 1962–1971.
221. Zhao, B., Li, L., Wang, L., Wang, C.Y., Yu, J., Guan, K.L., Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 26 (2012), 54–68.
222. Zhou, D., Conrad, C., Xia, F., Park, J.S., Payer, B., Yin, Y., Lauwers, G.Y., Thasler, W., Lee, J.T., Avruch, J., Bardeesy, N., Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16 (2009), 425–438.
223. Zhou, D., Zhang, Y., Wu, H., Barry, E., Yin, Y., Lawrence, E., Dawson, D., Willis, J.E., Markowitz, S.D., Camargo, F.D., Avruch, J., Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc. Natl. Acad. Sci. USA 108 (2011), E1312–E1320.
224. Zhou, Z., Hao, Y., Liu, N., Raptis, L., Tsao, M.S., Yang, X., TAZ is a novel oncogene in non-small cell lung cancer. Oncogene 30 (2011), 2181–2186.